

**Supplement 4. Details regarding treatment and follow-up of studies included in the systematic review.**

<b>Author / year</b>	<b>RT doses</b>	<b>Chemotherapy regimens</b>	<b>Chemotherapy cycles</b>	<b>Follow- up time and Schedule</b>
Kim 2013	50.4 Gy, consisting of 1.8-2 Gy fractions Parametrium was boosted to 60.4 Gy	Paclitaxel (175 mg/m <sup>2</sup> )/carboplatin (AUC 5) every three weeks, 5-fluorouracil (1,000 mg/m <sup>2</sup> for five consecutive days)/cisplatin (60 mg/m <sup>2</sup> on the first day) every three weeks, or cisplatin (70 mg/m <sup>2</sup> ) or carboplatin (AUC 5) alone every three weeks.	3-12 cycles. Ten patients received $\geq 6$ cycles.	The median follow-up was 20.3 months (1.8 to 83.8 months). No more details
Oishi 2016	Combination EBRT of 29-50.4 Gy (median: 50 Gy) and high-dose-rate intracavitary brachytherapy of 6-18 Gy in 1-3 fractions at point A.	The chemotherapy regimens used were cisplatin alone, cisplatin combination, weekly paclitaxel, and paclitaxel and carboplatin combination.	Not specified	Median follow-up was 9 months (1-194 months) Follow-up examinations were conducted every month for the first year, every 2 months for the second year, and subsequently every 3-6 months thereafter.
Wang 2018	EBRT with a dose $>45$ Gy	Not specified	Not specified	Median follow-up was 13.6 months (0.1-151). No more details
Li 2019	Not reported	Chemotherapy regimens consisted of TP, EP or another platinum-based regimen. TP represented for paclitaxel (135 mg/m <sup>2</sup> ) or docetaxel (75 mg/m <sup>2</sup> ) combined with cisplatin (60–80 mg/m <sup>2</sup> ) or nedaplatin (80 mg/m <sup>2</sup> ), oxaliplatin (130 mg/m <sup>2</sup> ) or carboplatin (AUC =5) every three weeks. EP represented for etoposide (120 mg/m <sup>2</sup> ) combined with cisplatin (60 mg/m <sup>2</sup> ). Other combined regimen consisted of docetaxel/carboplatin/5-Fu or vinorelbine/cisplatin/5-Fu every three weeks. Nine patients underwent chemotherapy with cisplatin-paclitaxel- bevacizumab regimen.	The median cycle of chemotherapy was 5 (range, 1–23)	Patients were followed up every 3 months for the first two years after the treatment, every 4 months for the 3rd year, every 6 months for the 4th and 5th years, and annually for the following years after that

Yin 2019	EBRT to a median dose of 45.9 Gy (range 45–50.4 Gy) in 1.7–1.8 Gy per fraction and brachytherapy to a median dose of 28 Gy	Platinum-containing doublet regimens mainly included cisplatin/paclitaxel, carboplatin/paclitaxel and cisplatin/etoposide every 21 or 28 days.	Median 4 cycles. All patients received at least two cycles.	Median follow-up was 14.4 months (4.6–114.7 months). Every 3 months for the first 2 years, then every 6 months for the next 3 years, and annually after that
Perkins 2020	Details regarding the sequence of chemotherapy and radiation and the dose and type of radiation were unable to be collected.	80.3% received a cisplatin-based regimen and 19.7% received carboplatin and paclitaxel. 26.2% in the chemotherapy alone group received bevacizumab.	Not reported	Median follow-up was 9 months (0–117).
Wiley 2022	Average dose for whole pelvic radiation was 50 Gy	All patients received at least three cycles of bevacizumab and platinum-based chemotherapy.	Mean 8.4 (6–9)	No details
Xu 2022	Not reported	Not reported	Not reported	Median follow-up was 16 months (1–107 months).

EBRT=External Beam Radiotherapy, RT= Radiotherapy